Latest News

Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

04 April 2023

  • Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)
  • Modulation of neuroinflammation by inducing FoxP3+ Tregs appears...

Read more

Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage

04 April 2023

  • Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke
  • Data shows behavioral outcomes improvement at one...

Read more

Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference

31 March 2023

  • Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD)
  • Modulation of neuroinflammation may be synergistic to...

Read more

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

28 March 2023

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS

  • First Phase 2 trial employing...

Read more

MEDIA: Jama Network: Nasally Administered Monoclonal Antibody for COVID-19

23 March 2023

March 22, 2023

Nasally Administered Monoclonal Antibody for COVID-19

Emily Harris

Article Information

JAMA. Published online March 22, 2023. doi:10.1001/jama.2023.4000

Treating people with mild to moderate COVID-19 infections nasally with foralumab, an anti-CD3 monoclonal antibody, decreases the expression of genes involved in...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

22 March 2023

New York, March 22, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

21 March 2023

New York, March 21, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

20 March 2023

New York, March 20, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

17 March 2023

NEW YORK, March 17, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its...

Read more

Tiziana Life Sciences Highlighted in Forbes Article

17 March 2023

Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases

NEW YORK, March 17, 2023...


Read more

Page 2 of 27 Previous Next